表紙
市場調査レポート

バーキットリンパ腫:パイプライン製品の分析

Burkitt Lymphoma - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213068
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
バーキットリンパ腫:パイプライン製品の分析 Burkitt Lymphoma - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 115 Pages
概要

バーキットリンパ腫とは、B細胞と呼ばれる免疫細胞に発生する癌である非ホジキンリンパ腫です。発熱や寝汗、リンパ節腫脹 体重減少などの症状があり、男性やHIV/AIDSなどの免疫不全患者により多く見られる疾患です。化学療法や放射線治療などの治療法があります。

当レポートでは、世界におけるバーキットリンパ腫治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

イントロダクション

  • 調査範囲

バーキットリンパ腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

バーキットリンパ腫:企業で開発中の治療薬

バーキットリンパ腫:大学/機関で研究中の治療薬

バーキットリンパ腫:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

バーキットリンパ腫:企業で開発中の製品

バーキットリンパ腫:大学/機関で研究中の製品

バーキットリンパ腫の治療薬開発に従事している企業

  • AbbVie Inc.
  • Arvinas, Inc.
  • AstraZeneca Plc
  • Bluebird bio, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Karyopharm Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • 武田薬品工業
  • Theravectys SA

バーキットリンパ腫:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

バーキットリンパ腫:最近のパイプライン動向

バーキットリンパ腫:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8048IDB

Summary

Global Markets Direct's, 'Burkitt Lymphoma - Pipeline Review, H1 2016', provides an overview of the Burkitt Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
  • The report reviews pipeline therapeutics for Burkitt Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Burkitt Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Burkitt Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Burkitt Lymphoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkitt Lymphoma Overview
  • Therapeutics Development
    • Pipeline Products for Burkitt Lymphoma - Overview
    • Pipeline Products for Burkitt Lymphoma - Comparative Analysis
  • Burkitt Lymphoma - Therapeutics under Development by Companies
  • Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Burkitt Lymphoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Burkitt Lymphoma - Products under Development by Companies
  • Burkitt Lymphoma - Products under Investigation by Universities/Institutes
  • Burkitt Lymphoma - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Arvinas, Inc.
    • AstraZeneca Plc
    • Bluebird bio, Inc.
    • Constellation Pharmaceuticals, Inc.
    • Immunomedics, Inc.
    • Karyopharm Therapeutics, Inc.
    • Millennium Pharmaceuticals, Inc.
    • Seattle Genetics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Theravectys SA
  • Burkitt Lymphoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 19-3s - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 20-3s - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARV-825 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-6738 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bb-2121 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denintuzumab mafodotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E1-3s - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Epstein-Barr virus vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SH-7129 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SH-7133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SH-7139 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BET for Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Burkitt Lymphoma - Recent Pipeline Updates
  • Burkitt Lymphoma - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkitt Lymphoma, H1 2016
  • Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Burkitt Lymphoma - Pipeline by AbbVie Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Arvinas, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by AstraZeneca Plc, H1 2016
  • Burkitt Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
  • Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Burkitt Lymphoma - Pipeline by Theravectys SA, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Burkitt Lymphoma - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Burkitt Lymphoma, H1 2016
  • Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top